facebook linkedin twitter

Pfizer, BioNTech COVID Vaccine Wins European Backing

December 22, 2020by Naomi Kresge and Suzi Ring, Bloomberg News (TNS)
Numbered inoculation cabins stand at the completed Covid-19 vaccination center at the Arena Berlin events venue during a visit by Federal President Frank-Walter Steinmeier on December 21, 2020 in Berlin, Germany. The vaccination center is one of six in Berlin and will likely begin offering inoculations beginning early January. The first vaccinations in Germany will likely begin December 27 with mobile teams inoculating staff and residents at nursing homes for senior citizens. (Christian Marquardt-Pool/Getty Images/TNS)

Pfizer Inc. and BioNTech SE’s COVID-19 vaccine won the backing of the European medicines regulator, clearing the way for inoculations to start before the end of the year as the continent struggles with rising death rates and tighter lockdowns.

The endorsement of the vaccine, Comirnaty, was announced in a news briefing by the European Medicines Agency on Monday. The final step in approval is a sign-off from the European Commission, expected later today.

“It is a significant step forward in our fight against this pandemic,” Emer Cooke, executive director of the agency, said in the meeting. “This is really a historic scientific achievement.”

EMA officials said there’s no evidence to suggest the vaccine won’t work against the new variant of the coronavirus that emerged in southeast England, leading to an emergency lockdown in London and causing countries including Canada, France and Germany to halt flights and suspend rail links.

European Union leaders pushed the regulator to speed up its review amid complaints that residents across the continent were still waiting to get a vaccine — pioneered in Germany — that is already being used in the U.K. and U.S. The goal is to start a European immunization campaign on Dec. 27, commission President Ursula von der Leyen said last week.

Monday’s recommendation puts the EU in position to meet that timeline. Von der Leyen said in a tweet that she expects the commission to act swiftly, with a decision by tonight.

The trials showed the vaccine was effective in preventing Covid-19 in people from 16 years of age, the agency said in a statement.

Just as Europe prepares to roll out the first vaccine, countries are suspending travel links to the U.K. amid an effort to contain a variant of the coronavirus that officials say is spreading quickly across London and southeast England.

Unlike the U.S. and U.K., which conducted emergency authorizations, the EMA reviewed the vaccine for a conditional marketing authorization. Such a decision requires more evidence, the EU commission’s directorate-general for health said last week. The EMA committee is also reviewing a similar vaccine from Moderna Inc., with a key meeting set for Jan. 6.

___

©2020 Bloomberg L.P.

Distributed by Tribune Content Agency, LLC

Health

October 20, 2021
by Dan McCue
FDA Signs Off on Moderna, J&J Boosters, Mixing Vaccines

WASHINGTON - The Food and Drug Administration on Wednesday said Americans who got either the Moderna or Johnson & Johnson... Read More

WASHINGTON - The Food and Drug Administration on Wednesday said Americans who got either the Moderna or Johnson & Johnson vaccine can now get a COVID-19 booster, and also say that those eligible for a booster don’t have to get the same brand as their initial... Read More

October 20, 2021
by Alexa Hornbeck
EPA Accelerates Efforts to Clean Up PFAS Pollution

This week, the Environmental Protection Agency released a new roadmap to accelerate efforts to protect Americans from per- and polyfluoroalkyl... Read More

This week, the Environmental Protection Agency released a new roadmap to accelerate efforts to protect Americans from per- and polyfluoroalkyl substances, a class of toxic chemicals found in food packaging and other common commercial products that can cause severe health problems. "We are exploring ways for... Read More

October 20, 2021
by Alexa Hornbeck
Developer of Gene Editing Tool Discusses Ethics of Emerging Treatments

It was only nine years ago that researchers discovered a method for editing human genes using a specialized technology called... Read More

It was only nine years ago that researchers discovered a method for editing human genes using a specialized technology called the CRISPR-Cas9 tool.   CRISPR-Cas9 enables geneticists and medical researchers to edit parts of the genome by removing, adding or altering sections of the DNA sequence.  Ethicists,... Read More

October 20, 2021
by Alexa Hornbeck
Middle-Aged Women at Higher Risk of ‘Broken Heart’ Syndrome

LOS ANGELES - A new study from researchers from Cedars-Sinai Medical Center appears to confirm what many have long argued:... Read More

LOS ANGELES - A new study from researchers from Cedars-Sinai Medical Center appears to confirm what many have long argued: That a “broken heart” really can lead to long-term heart injury. “We know from other studies the heart-brain connection is very strong, but this is one... Read More

White House Details Plans to Vaccinate 28M Children Age 5-11

WASHINGTON (AP) — Children age 5 to 11 will soon be able to get a COVID-19 shot at their pediatrician's... Read More

WASHINGTON (AP) — Children age 5 to 11 will soon be able to get a COVID-19 shot at their pediatrician's office, local pharmacy and potentially even their school, the White House said Wednesday as it detailed plans for the expected authorization of the Pfizer shot for... Read More

Pig-to-Human Transplants Come a Step Closer with New Test

Scientists temporarily attached a pig's kidney to a human body and watched it begin to work, a small step in... Read More

Scientists temporarily attached a pig's kidney to a human body and watched it begin to work, a small step in the decades-long quest to one day use animal organs for life-saving transplants. Pigs have been the most recent research focus to address the organ shortage, but... Read More

News From The Well
scroll top